SOD1 and amyotrophic lateral sclerosis: The study conducted by Gaj et al. demonstrated disruption of mutant SOD1 expression in the G93A-SOD1 mouse model of ALS through in vivo CRISPR-Cas9 genome editing using an AAV vector can result in delayed disease onset, improved motor function, and reduced muscle atrophy [52].